The Brand Name REFUR-B Has Generic Salt :: Beclomethasone
REFUR-B Is From Company Stanford Priced :: Rs. 16.75/27.75
REFUR-B have Beclomethasone is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Asthma, Chronic obstructive pulmonary disease (COPD),
Drug Dose ::
Management of chronic asthma Adults & children over 12 years: 100-400 mcg twice daily. Children (5-12 years): 100-200 mcg twice daily. Maximum 200-400 mcg twice daily. Prophylaxis of asthma Adults & children over 12 years: 50-200 mcg twice daily. Increased if necessary to maximum 400 mcg twice daily. Children (5-12 years): The usual starting dose is 100 mcg twice daily. Depending on the severity of asthma, the daily dose may be increased up to 400 mcg administered in 2-4 divided doses. When patient’s symptoms remain under satisfactory control, the dose should be titrated to the lowest dose at which effective control of asthma is maintained.
Hypersensitivity to any of the ingredients of this preparation contraindicates its use. Child under 6 years not recommended.
Drug Precautions ::
Patients should be instructed to use inhaler properly to ensure that the drug reaches the target areas within the lungs. They should also be made aware of the prophylactic nature of therapy with Beclometasone Dipropionate HFA inhaler and that they should use it regularly, even when they are asymptomatic. Intranasal corticosteroids may cause a reduction in growth velocity when administered to pediatric patients. Beclometasone dipropionate is not suitable for the treatment of an acute asthma attack.
Drug Side Effects ::
Loss of skin collagen and SC atrophy; local hypopigmentation of deeply pigmented skin; dryness, irritation, epistaxis, rarely ulceration or perforation of the nasal septum; smell and taste disturbances; hoarseness and candidiasis of the mouth or throat.
Pregnancy category ::
Drug Mode of Action ::
Beclometasone controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes, fibroblasts, reverses capillary permeability and lysosomal stabilisation at the cellular level to prevent or control inflammation.
Drug Interactions ::
Inhibitors of CYP3A4: potential pharmacokinetic interaction (increased plasma beclomethasone dipropionate concentrations). Inducers of CYP3A4: potential pharmacokinetic interaction (decreased plasma beclomethasone dipropionate concentrations). Antidiabetic agents May increase blood glucose concentrations in patients with diabetes mellitus. NSAIDs Possible increased risk of GI ulcerationa Decreased serum salicylate concentrations. When corticosteroids are discontinued, serum salicylate concentration may increase possibly resulting in salicylate intoxication Vaccines and Toxoids May cause a diminished response to toxoids and live or inactivated vaccines. May potentiate replication of some organisms contained in live, attenuated vaccines. Can aggravate neurologic reactions to some vaccines (supraphysiologic dosages).